S
SineuGene Therapeutics
Biopharmaceutical company specializing in gene therapy for brain disorders, leveraging research from Tsinghua University's School of Medicine, and focusing on new AAV capsid variations for CNS gene…
About SineuGene Therapeutics
SineuGene Therapeutics is a biopharmaceutical company specializing in gene therapy for brain disorders. Founded in late 2021, the company leverages over a decade of neuroscience research from JiaLab at Tsinghua University's School of Medicine. SineuGene focuses on developing effective and safe gene therapy solutions for patients suffering from neurodegenerative diseases. The company has established a comprehensive platform for developing central nervous system (CNS) small nucleic acid drugs, which includes target screening, sequence design optimization, nucleic acid synthesis, chemical modifications, and delivery technology development. SineuGene collaborates with PackGene to screen for new AAV capsid variants specifically targeting the CNS, aiming to accelerate gene therapy advancements. The business model revolves around extensive research and development, clinical trials, and partnerships to bring innovative therapies to market. Revenue is generated through the development and commercialization of gene therapy products, as well as potential licensing agreements and collaborations with other biopharmaceutical companies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Aug 2024 | $14M | $55M | Transfar Chemicals · Sanmei Investment · Zhongguancun Development Group · Zhongbo Juli | ↗ |
| SEED✓Equity / VC | Oct 2023 | $2.8M | $46M | Beige Capital | ↗ |
Growth signals
Latest recorded traffic for SineuGene Therapeutics is 980 monthly website visits, down 2% over the last three months. SineuGene Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
SineuGene Therapeutics in its local ecosystem
The SineuGene Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
- SFShanghai Fengcang Innovation Fund
MSA Capital- BCBeige Capital
Zhongguancun Development Group
Transfar Chemicals- SISanmei Investment
- ZJZhongbo Juli
Other known investors1 additional known investor
Tsinghua University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SineuGene Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SineuGene Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










